Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

The addition of atezolizumab (anti-PD-L1) to enzalutamide (androgen receptor antagonist) did not prolong survival in metastatic prostate cancer.1 Efficacy with immunotherapies in prostate cancer will require additional studies to elucidate and target mechanisms of resistance within the prostate tumor microenvironment.

Original languageEnglish (US)
Article number100613
JournalCell Reports Medicine
Volume3
Issue number4
DOIs
StatePublished - Apr 19 2022

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Medicine

Fingerprint

Dive into the research topics of 'Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer'. Together they form a unique fingerprint.

Cite this